troglitazone antidiabetic antiinflammatory drug member drug class thiazolidinediones prescribed people diabetes mellitus type patented approved medical use subsequently withdrawn troglitazone like thiazolidinediones pioglitazone rosiglitazone works activating peroxisome proliferatoractivated receptors ppars troglitazone ligand pparα strongly pparγ troglitazone also contains αtocopherol moiety potentially giving vitamin elike activity addition ppar activation shown reduce troglitazone use associated decrease nuclear factor kappab nfκb concomitant increase inhibitor iκb nfκb important cellular transcription regulator immune response troglitazone developed daiichi sankyo japan united states introduced manufactured parkedavis late turned associated idiosyncratic reaction leading druginduced hepatitis food drug administration fda medical officer assigned evaluate troglitazone john gueriguian recommend approval due potentially high liver toxicity parkedavis complained fda gueriguian subsequently removed panel experts approved january prevalence adverse liver effects became known troglitazone withdrawn british market december united states market japanese market soon afterwards get approval rest europe troglitazone developed first antidiabetic drug mechanism action involving enhancement insulin resistance time widely believed drugs addressing primary metabolic defect associated type diabetes would numerous benefits including avoiding risk hypoglycemia associated insulin earlier oral antidiabetic drugs believed reducing insulin resistance would potentially reduce high rate cardiovascular disease associated parkedaviswarner lambert submitted diabetes drug rezulin fda review july medical officer assigned review dr john l gueriguian cited rezulins potential harm liver heart questioned viability lowering blood sugar patients adultonset diabetes recommending drugs approval complaints drugmaker gueriguian removed november review purged gueriguian company single meeting gueriguian used intemperate language company said objections based inappropriate remarks made parkedavis said advisory committee risk liver toxicity comparable placebo additional data studies confirmed according peter gøtzsche company provided additional data one week approval showed substantially greater risk liver fda approved drug january appeared pharmacies late march time dr solomon sobel director fda overseeing diabetes drugs said new york times interview adverse effects troglitazone appeared rare relatively glaxo wellcome received approval british medicines control agency mca market troglitazone romozin july reports sudden liver failure patients receiving drug parkedavis fda added warnings drug label requiring monthly monitoring liver enzyme glaxo wellcome removed troglitazone market britain december glaxo wellcome licensed drug sankyo company japan sold britain october may patient named audrey larue jones died acute liver failure taking troglitazone importantly monitored closely physicians national institutes health nih participant national institute diabetes digestive kidney diseases niddk diabetes prevention called question efficacy monitoring strategy nih responded june dropping troglitazone dr david j graham fda epidemiologist charged evaluating drug warned march dangers using concluded patient monitoring effective protecting liver failure estimated drug could linked liver failures patients incurred times greater risk liver failure taking dr janet b mcgill endocrinologist assisted early clinical testing rezulin wrote march letter sen edward kennedy dmass believe company deliberately omitted reports liver toxicity misrepresented serious adverse events experienced patients clinical march fda withdrew drug dr robert misbin fda medical officer wrote march letter senator john ashcroft strong evidence rezulin could used safely later threatened fda dismissal time drug linked liverfailure deaths generated sales billion drug cost year per patient pfizer acquired warnerlambert february reported withdrawal rezulin cost since withdrawal mechanisms troglitazone hepatotoxicity extensively studied using variety computational studies suggested hepatotoxicity troglitazone results combination metabolic nonmetabolic nonmetabolic toxicity complex function drugprotein interactions liver biliary system initially metabolic toxicity largely associated reactive metabolite formation thiazolidinedione chromane rings troglitazone moreover formation quinone oquinone methide reactive metabolites proposed formed metabolic oxidation hydroxy group oh group chromane detailed quantum chemical analysis metabolic pathways troglitazone shown quinone reactive metabolite generated oxidation oh group oquinone methide reactive metabolite formed oxidation methyl groups groups ortho oh group chromane understanding recently used design novel troglitazone derivatives antiproliferative activity breast cancer cell pfizer resolved three claims withdrawn diabetes drug rezulin total million pfizer acquired rival wyeth almost billion paid million settle rezulin cases consolidated federal court new york according court filings company also paid much million resolve statecourt suits set aside million end rezulin httpsenwikipediaorgwikitroglitazone